Derivation Web

source_d336161e46d440f8

by researka:v2 · 2026-07-10 12:09:14.168444+04:00

{"publication_id": "d8f38608-04e9-4baf-a98a-b15cef29f955", "traces": [{"candidate_sources": [{"directness": "review-level", "doi": "10.1186/s12902-024-01805-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_1", "study": "Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12902-024-01805-z"}, {"directness": "primary", "doi": "10.1111/jdi.13789", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_2", "study": "A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1111/jdi.13789"}, {"directness": "primary", "doi": "10.1186/s40001-025-02836-5", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_3", "study": "Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s40001-025-02836-5"}, {"directness": "review-level", "doi": "10.1186/s12905-025-03787-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_4", "study": "The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12905-025-03787-z"}, {"directness": "primary", "doi": "10.1097/JS9.0000000000000990", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_5", "study": "Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1097/JS9.0000000000000990"}], "claim": "Evidence-honesty note: 43/56 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.", "claim_id": "claim_1"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1186/s12902-024-01805-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_1", "study": "Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12902-024-01805-z"}, {"directness": "primary", "doi": "10.1111/jdi.13789", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_2", "study": "A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1111/jdi.13789"}, {"directness": "primary", "doi": "10.1186/s40001-025-02836-5", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_3", "study": "Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s40001-025-02836-5"}, {"directness": "review-level", "doi": "10.1186/s12905-025-03787-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_4", "study": "The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12905-025-03787-z"}, {"directness": "primary", "doi": "10.1097/JS9.0000000000000990", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_5", "study": "Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1097/JS9.0000000000000990"}], "claim": "We applied an AI-assisted structured evidence synthesis with an explicit audit trail, restricting the analytic frame to direct human randomized or longitudinal evidence on liraglutide and separating it from mechanistic or cross-domain signals.", "claim_id": "claim_2"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1186/s12902-024-01805-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_1", "study": "Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12902-024-01805-z"}, {"directness": "primary", "doi": "10.1111/jdi.13789", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_2", "study": "A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1111/jdi.13789"}, {"directness": "primary", "doi": "10.1186/s40001-025-02836-5", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_3", "study": "Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s40001-025-02836-5"}, {"directness": "review-level", "doi": "10.1186/s12905-025-03787-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_4", "study": "The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12905-025-03787-z"}, {"directness": "primary", "doi": "10.1097/JS9.0000000000000990", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_5", "study": "Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1097/JS9.0000000000000990"}], "claim": "Evidence-abstraction note.** The 56 retained reference papers are not 56 independent primary clinical trials: 43 are review, indirect, mechanistic, or registered-protocol source-level summaries, and 13 are classified as direct interventional evidence. Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence.", "claim_id": "claim_3"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1186/s12902-024-01805-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_1", "study": "Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12902-024-01805-z"}, {"directness": "primary", "doi": "10.1111/jdi.13789", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_2", "study": "A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1111/jdi.13789"}, {"directness": "primary", "doi": "10.1186/s40001-025-02836-5", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_3", "study": "Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s40001-025-02836-5"}, {"directness": "review-level", "doi": "10.1186/s12905-025-03787-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_4", "study": "The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12905-025-03787-z"}, {"directness": "primary", "doi": "10.1097/JS9.0000000000000990", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_5", "study": "Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1097/JS9.0000000000000990"}], "claim": "This synthesis evaluates evidence on liraglutide biomarker effects across 56 included source papers and 3841 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, adjacent/review/context evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.", "claim_id": "claim_4"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1186/s12902-024-01805-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_1", "study": "Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12902-024-01805-z"}, {"directness": "primary", "doi": "10.1111/jdi.13789", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_2", "study": "A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1111/jdi.13789"}, {"directness": "primary", "doi": "10.1186/s40001-025-02836-5", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_3", "study": "Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s40001-025-02836-5"}, {"directness": "review-level", "doi": "10.1186/s12905-025-03787-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_4", "study": "The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12905-025-03787-z"}, {"directness": "primary", "doi": "10.1097/JS9.0000000000000990", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_5", "study": "Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1097/JS9.0000000000000990"}], "claim": "The corpus contains 13 direct clinical sources, 42 adjacent, review, or context sources, and 1 mechanistic or model-system source. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.", "claim_id": "claim_5"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1186/s12902-024-01805-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_1", "study": "Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12902-024-01805-z"}, {"directness": "primary", "doi": "10.1111/jdi.13789", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_2", "study": "A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1111/jdi.13789"}, {"directness": "primary", "doi": "10.1186/s40001-025-02836-5", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_3", "study": "Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s40001-025-02836-5"}, {"directness": "review-level", "doi": "10.1186/s12905-025-03787-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_4", "study": "The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12905-025-03787-z"}, {"directness": "primary", "doi": "10.1097/JS9.0000000000000990", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_5", "study": "Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1097/JS9.0000000000000990"}], "claim": "The introductory frame therefore treats the corpus as a set of evidence roles rather than a single directional verdict. Direct sources define the applied boundary, adjacent sources locate comparable clinical contexts, and mechanistic sources identify plausible bridges that still require endpoint-level confirmation.", "claim_id": "claim_6"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1186/s12902-024-01805-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_1", "study": "Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12902-024-01805-z"}, {"directness": "primary", "doi": "10.1111/jdi.13789", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_2", "study": "A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1111/jdi.13789"}, {"directness": "primary", "doi": "10.1186/s40001-025-02836-5", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_3", "study": "Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s40001-025-02836-5"}, {"directness": "review-level", "doi": "10.1186/s12905-025-03787-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_4", "study": "The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12905-025-03787-z"}, {"directness": "primary", "doi": "10.1097/JS9.0000000000000990", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_5", "study": "Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1097/JS9.0000000000000990"}], "claim": "This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.", "claim_id": "claim_7"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1186/s12902-024-01805-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_1", "study": "Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12902-024-01805-z"}, {"directness": "primary", "doi": "10.1111/jdi.13789", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_2", "study": "A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1111/jdi.13789"}, {"directness": "primary", "doi": "10.1186/s40001-025-02836-5", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_3", "study": "Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s40001-025-02836-5"}, {"directness": "review-level", "doi": "10.1186/s12905-025-03787-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_4", "study": "The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12905-025-03787-z"}, {"directness": "primary", "doi": "10.1097/JS9.0000000000000990", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_5", "study": "Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1097/JS9.0000000000000990"}], "claim": "The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.", "claim_id": "claim_8"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1186/s12902-024-01805-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_1", "study": "Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12902-024-01805-z"}, {"directness": "primary", "doi": "10.1111/jdi.13789", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_2", "study": "A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1111/jdi.13789"}, {"directness": "primary", "doi": "10.1186/s40001-025-02836-5", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_3", "study": "Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s40001-025-02836-5"}, {"directness": "review-level", "doi": "10.1186/s12905-025-03787-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_4", "study": "The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12905-025-03787-z"}, {"directness": "primary", "doi": "10.1097/JS9.0000000000000990", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_5", "study": "Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1097/JS9.0000000000000990"}], "claim": "Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.", "claim_id": "claim_9"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1186/s12902-024-01805-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_1", "study": "Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12902-024-01805-z"}, {"directness": "primary", "doi": "10.1111/jdi.13789", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_2", "study": "A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1111/jdi.13789"}, {"directness": "primary", "doi": "10.1186/s40001-025-02836-5", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_3", "study": "Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s40001-025-02836-5"}, {"directness": "review-level", "doi": "10.1186/s12905-025-03787-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_4", "study": "The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12905-025-03787-z"}, {"directness": "primary", "doi": "10.1097/JS9.0000000000000990", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_5", "study": "Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1097/JS9.0000000000000990"}], "claim": "Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.", "claim_id": "claim_10"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1186/s12902-024-01805-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_1", "study": "Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12902-024-01805-z"}, {"directness": "primary", "doi": "10.1111/jdi.13789", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_2", "study": "A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1111/jdi.13789"}, {"directness": "primary", "doi": "10.1186/s40001-025-02836-5", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_3", "study": "Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s40001-025-02836-5"}, {"directness": "review-level", "doi": "10.1186/s12905-025-03787-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_4", "study": "The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12905-025-03787-z"}, {"directness": "primary", "doi": "10.1097/JS9.0000000000000990", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_5", "study": "Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1097/JS9.0000000000000990"}], "claim": "The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.", "claim_id": "claim_11"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1186/s12902-024-01805-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_1", "study": "Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12902-024-01805-z"}, {"directness": "primary", "doi": "10.1111/jdi.13789", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_2", "study": "A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1111/jdi.13789"}, {"directness": "primary", "doi": "10.1186/s40001-025-02836-5", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_3", "study": "Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s40001-025-02836-5"}, {"directness": "review-level", "doi": "10.1186/s12905-025-03787-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_4", "study": "The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12905-025-03787-z"}, {"directness": "primary", "doi": "10.1097/JS9.0000000000000990", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_5", "study": "Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1097/JS9.0000000000000990"}], "claim": "For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.", "claim_id": "claim_12"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1186/s12902-024-01805-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_1", "study": "Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12902-024-01805-z"}, {"directness": "primary", "doi": "10.1111/jdi.13789", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_2", "study": "A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1111/jdi.13789"}, {"directness": "primary", "doi": "10.1186/s40001-025-02836-5", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_3", "study": "Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s40001-025-02836-5"}, {"directness": "review-level", "doi": "10.1186/s12905-025-03787-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_4", "study": "The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12905-025-03787-z"}, {"directness": "primary", "doi": "10.1097/JS9.0000000000000990", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_5", "study": "Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1097/JS9.0000000000000990"}], "claim": "The research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge.", "claim_id": "claim_13"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1186/s12902-024-01805-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_1", "study": "Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12902-024-01805-z"}, {"directness": "primary", "doi": "10.1111/jdi.13789", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_2", "study": "A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1111/jdi.13789"}, {"directness": "primary", "doi": "10.1186/s40001-025-02836-5", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_3", "study": "Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s40001-025-02836-5"}, {"directness": "review-level", "doi": "10.1186/s12905-025-03787-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_4", "study": "The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12905-025-03787-z"}, {"directness": "primary", "doi": "10.1097/JS9.0000000000000990", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_5", "study": "Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1097/JS9.0000000000000990"}], "claim": "Additional corpus sources included animal/preclinical evidence; the background evidence for liraglutide biomarker effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Seino 2022, Hany 2023, Pandey 2024 are interpreted separately from mechanistic studies such as Long 2025, because these evidence roles answer different questions about aging biology and clinical translation.", "claim_id": "claim_14"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1186/s12902-024-01805-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_1", "study": "Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12902-024-01805-z"}, {"directness": "primary", "doi": "10.1111/jdi.13789", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_2", "study": "A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1111/jdi.13789"}, {"directness": "primary", "doi": "10.1186/s40001-025-02836-5", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_3", "study": "Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s40001-025-02836-5"}, {"directness": "review-level", "doi": "10.1186/s12905-025-03787-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_4", "study": "The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12905-025-03787-z"}, {"directness": "primary", "doi": "10.1097/JS9.0000000000000990", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_5", "study": "Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1097/JS9.0000000000000990"}], "claim": "The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.", "claim_id": "claim_15"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1186/s12902-024-01805-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_1", "study": "Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12902-024-01805-z"}, {"directness": "primary", "doi": "10.1111/jdi.13789", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_2", "study": "A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1111/jdi.13789"}, {"directness": "primary", "doi": "10.1186/s40001-025-02836-5", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_3", "study": "Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s40001-025-02836-5"}, {"directness": "review-level", "doi": "10.1186/s12905-025-03787-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_4", "study": "The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12905-025-03787-z"}, {"directness": "primary", "doi": "10.1097/JS9.0000000000000990", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_5", "study": "Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1097/JS9.0000000000000990"}], "claim": "Across the retained sources, positive signals cluster around the cardiometabolic outcome class; null signals around the cardiometabolic and contextual adjacent evidence outcome classes; and negative or adverse signals around the cardiometabolic and contextual adjacent evidence outcome classes. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.", "claim_id": "claim_16"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1186/s12902-024-01805-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_1", "study": "Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12902-024-01805-z"}, {"directness": "primary", "doi": "10.1111/jdi.13789", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_2", "study": "A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1111/jdi.13789"}, {"directness": "primary", "doi": "10.1186/s40001-025-02836-5", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_3", "study": "Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s40001-025-02836-5"}, {"directness": "review-level", "doi": "10.1186/s12905-025-03787-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_4", "study": "The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12905-025-03787-z"}, {"directness": "primary", "doi": "10.1097/JS9.0000000000000990", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_5", "study": "Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1097/JS9.0000000000000990"}], "claim": "The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.", "claim_id": "claim_17"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1186/s12902-024-01805-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_1", "study": "Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12902-024-01805-z"}, {"directness": "primary", "doi": "10.1111/jdi.13789", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_2", "study": "A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1111/jdi.13789"}, {"directness": "primary", "doi": "10.1186/s40001-025-02836-5", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_3", "study": "Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s40001-025-02836-5"}, {"directness": "review-level", "doi": "10.1186/s12905-025-03787-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_4", "study": "The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12905-025-03787-z"}, {"directness": "primary", "doi": "10.1097/JS9.0000000000000990", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_5", "study": "Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1097/JS9.0000000000000990"}], "claim": "The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.", "claim_id": "claim_18"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1186/s12902-024-01805-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_1", "study": "Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12902-024-01805-z"}, {"directness": "primary", "doi": "10.1111/jdi.13789", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_2", "study": "A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1111/jdi.13789"}, {"directness": "primary", "doi": "10.1186/s40001-025-02836-5", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_3", "study": "Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s40001-025-02836-5"}, {"directness": "review-level", "doi": "10.1186/s12905-025-03787-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_4", "study": "The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12905-025-03787-z"}, {"directness": "primary", "doi": "10.1097/JS9.0000000000000990", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_5", "study": "Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1097/JS9.0000000000000990"}], "claim": "The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.", "claim_id": "claim_19"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1186/s12902-024-01805-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_1", "study": "Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12902-024-01805-z"}, {"directness": "primary", "doi": "10.1111/jdi.13789", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_2", "study": "A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1111/jdi.13789"}, {"directness": "primary", "doi": "10.1186/s40001-025-02836-5", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_3", "study": "Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s40001-025-02836-5"}, {"directness": "review-level", "doi": "10.1186/s12905-025-03787-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_4", "study": "The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12905-025-03787-z"}, {"directness": "primary", "doi": "10.1097/JS9.0000000000000990", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_5", "study": "Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1097/JS9.0000000000000990"}], "claim": "Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.", "claim_id": "claim_20"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1186/s12902-024-01805-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_1", "study": "Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12902-024-01805-z"}, {"directness": "primary", "doi": "10.1111/jdi.13789", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_2", "study": "A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1111/jdi.13789"}, {"directness": "primary", "doi": "10.1186/s40001-025-02836-5", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_3", "study": "Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s40001-025-02836-5"}, {"directness": "review-level", "doi": "10.1186/s12905-025-03787-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_4", "study": "The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12905-025-03787-z"}, {"directness": "primary", "doi": "10.1097/JS9.0000000000000990", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_5", "study": "Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1097/JS9.0000000000000990"}], "claim": "Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, longevity, mechanism); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.", "claim_id": "claim_21"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1186/s12902-024-01805-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_1", "study": "Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12902-024-01805-z"}, {"directness": "primary", "doi": "10.1111/jdi.13789", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_2", "study": "A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1111/jdi.13789"}, {"directness": "primary", "doi": "10.1186/s40001-025-02836-5", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_3", "study": "Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s40001-025-02836-5"}, {"directness": "review-level", "doi": "10.1186/s12905-025-03787-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_4", "study": "The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12905-025-03787-z"}, {"directness": "primary", "doi": "10.1097/JS9.0000000000000990", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_5", "study": "Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1097/JS9.0000000000000990"}], "claim": "Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.", "claim_id": "claim_22"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1186/s12902-024-01805-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_1", "study": "Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12902-024-01805-z"}, {"directness": "primary", "doi": "10.1111/jdi.13789", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_2", "study": "A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1111/jdi.13789"}, {"directness": "primary", "doi": "10.1186/s40001-025-02836-5", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_3", "study": "Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s40001-025-02836-5"}, {"directness": "review-level", "doi": "10.1186/s12905-025-03787-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_4", "study": "The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12905-025-03787-z"}, {"directness": "primary", "doi": "10.1097/JS9.0000000000000990", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_5", "study": "Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1097/JS9.0000000000000990"}], "claim": "| Evidence domain | Source | Direction | Directness | Tier | Evidence role | Finding |", "claim_id": "claim_23"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1186/s12902-024-01805-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_1", "study": "Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12902-024-01805-z"}, {"directness": "primary", "doi": "10.1111/jdi.13789", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_2", "study": "A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1111/jdi.13789"}, {"directness": "primary", "doi": "10.1186/s40001-025-02836-5", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_3", "study": "Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s40001-025-02836-5"}, {"directness": "review-level", "doi": "10.1186/s12905-025-03787-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_4", "study": "The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12905-025-03787-z"}, {"directness": "primary", "doi": "10.1097/JS9.0000000000000990", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_5", "study": "Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1097/JS9.0000000000000990"}], "claim": "| Cardiometabolic | Bonga 2026: Incretin Analogues for Weight Reduction in Non-Diabetic Obese: A Review of Liraglutide, Semaglutide, and Tirzepatide Beyond Glycemic Control | direction=null | directness=indirect | B2 | outcome=Cardiometabolic; direction=null | finding=1 extracted claim(s); source-level direction is the coded finding |", "claim_id": "claim_24"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1186/s12902-024-01805-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_1", "study": "Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12902-024-01805-z"}, {"directness": "primary", "doi": "10.1111/jdi.13789", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_2", "study": "A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1111/jdi.13789"}, {"directness": "primary", "doi": "10.1186/s40001-025-02836-5", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_3", "study": "Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s40001-025-02836-5"}, {"directness": "review-level", "doi": "10.1186/s12905-025-03787-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_4", "study": "The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12905-025-03787-z"}, {"directness": "primary", "doi": "10.1097/JS9.0000000000000990", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_5", "study": "Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1097/JS9.0000000000000990"}], "claim": "| Cardiometabolic | Dhippayom 2026: GLP ‐1 receptor agonists for treating obesity without diabetes: A systematic review and meta‐analysis of economic evaluations | direction=null | directness=review | B2 | outcome=Cardiometabolic; direction=null | finding=45 extracted claim(s); source-level direction is the coded finding |", "claim_id": "claim_25"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1186/s12902-024-01805-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_1", "study": "Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12902-024-01805-z"}, {"directness": "primary", "doi": "10.1111/jdi.13789", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_2", "study": "A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1111/jdi.13789"}, {"directness": "primary", "doi": "10.1186/s40001-025-02836-5", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_3", "study": "Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s40001-025-02836-5"}, {"directness": "review-level", "doi": "10.1186/s12905-025-03787-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_4", "study": "The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12905-025-03787-z"}, {"directness": "primary", "doi": "10.1097/JS9.0000000000000990", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_5", "study": "Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1097/JS9.0000000000000990"}], "claim": "| Cardiometabolic | Dong 2025: Long-term administration of liraglutide for weight management in pediatric patients under 18 years: evidence from 7 randomized controlled trials. | direction=positive | directness=direct | A1 | outcome=Cardiometabolic; direction=positive | finding=representative statistic P = 0.007; source-level statistic reported |", "claim_id": "claim_26"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1186/s12902-024-01805-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_1", "study": "Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12902-024-01805-z"}, {"directness": "primary", "doi": "10.1111/jdi.13789", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_2", "study": "A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1111/jdi.13789"}, {"directness": "primary", "doi": "10.1186/s40001-025-02836-5", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_3", "study": "Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s40001-025-02836-5"}, {"directness": "review-level", "doi": "10.1186/s12905-025-03787-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_4", "study": "The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12905-025-03787-z"}, {"directness": "primary", "doi": "10.1097/JS9.0000000000000990", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_5", "study": "Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1097/JS9.0000000000000990"}], "claim": "| Cardiometabolic | Fang 2026: Effect of liraglutide on depressive symptoms in overweight or obese patients with type 2 diabetes: protocol for a pilot randomized controlled trial | direction=null | directness=direct | A1 | outcome=Cardiometabolic; direction=null | finding=6 extracted claim(s); source-level direction is the coded finding |", "claim_id": "claim_27"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1186/s12902-024-01805-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_1", "study": "Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12902-024-01805-z"}, {"directness": "primary", "doi": "10.1111/jdi.13789", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_2", "study": "A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1111/jdi.13789"}, {"directness": "primary", "doi": "10.1186/s40001-025-02836-5", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_3", "study": "Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s40001-025-02836-5"}, {"directness": "review-level", "doi": "10.1186/s12905-025-03787-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_4", "study": "The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12905-025-03787-z"}, {"directness": "primary", "doi": "10.1097/JS9.0000000000000990", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_5", "study": "Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1097/JS9.0000000000000990"}], "claim": "| Cardiometabolic | Huang 2025: The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis | direction=unclear | directness=review | B2 | outcome=Cardiometabolic; direction=unclear | finding=representative non-significant statistic P = 0.41; not treated as positive or negative directional support unless source direction is coded |", "claim_id": "claim_28"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1186/s12902-024-01805-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_1", "study": "Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12902-024-01805-z"}, {"directness": "primary", "doi": "10.1111/jdi.13789", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_2", "study": "A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1111/jdi.13789"}, {"directness": "primary", "doi": "10.1186/s40001-025-02836-5", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_3", "study": "Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s40001-025-02836-5"}, {"directness": "review-level", "doi": "10.1186/s12905-025-03787-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_4", "study": "The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12905-025-03787-z"}, {"directness": "primary", "doi": "10.1097/JS9.0000000000000990", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_5", "study": "Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1097/JS9.0000000000000990"}], "claim": "| Cardiometabolic | Lu 2026b: Efficacy of liraglutide on metabolic and reproductive outcomes in women with polycystic ovary syndrome: A systematic review and meta-analysis. | direction=null | directness=review | B1 | outcome=Cardiometabolic; direction=null | finding=1 extracted claim(s); source-level direction is the coded finding |", "claim_id": "claim_29"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1186/s12902-024-01805-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_1", "study": "Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12902-024-01805-z"}, {"directness": "primary", "doi": "10.1111/jdi.13789", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_2", "study": "A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1111/jdi.13789"}, {"directness": "primary", "doi": "10.1186/s40001-025-02836-5", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_3", "study": "Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s40001-025-02836-5"}, {"directness": "review-level", "doi": "10.1186/s12905-025-03787-z", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_4", "study": "The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12905-025-03787-z"}, {"directness": "primary", "doi": "10.1097/JS9.0000000000000990", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_5", "study": "Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1097/JS9.0000000000000990"}], "claim": "| Cardiometabolic | Mahzari 2024: Retinopathy risk factors in patients with type 2 diabetes on liraglutide | direction=mixed | directness=indirect | B2 | outcome=Cardiometabolic; direction=mixed | finding=representative statistic P < 0.001; source-level statistic reported |", "claim_id": "claim_30"}]}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "d8f38608-04e9-4baf-a98a-b15cef29f955",
  "researka_submission_id": "3b55c07b-acb3-4a2c-bd24-ae0c9c9f8c27",
  "sidecar_name": "citation_traces.json",
  "sidecar_url": "https://api.researka.org/publications/d8f38608-04e9-4baf-a98a-b15cef29f955/sidecars/citation_traces.json"
}